The Journal of Heart and Lung Transplantation
International Society for Heart and Lung Transplantation.
Original clinical science| Volume 30, ISSUE 6, P679-684, June 2011

Download started.


Low-dose intradermal versus intramuscular trivalent inactivated seasonal influenza vaccine in lung transplant recipients


      In this study we compared the immunogenicity of influenza vaccine administered intradermally to the standard intramuscular vaccination in lung transplant recipients.


      Patients were randomized to receive the trivalent inactivated seasonal 2008–9 influenza vaccine containing either 6 μg (intradermal) or 15 μg (intramuscular) of hemagglutinin per viral strain. Immunogenicity was assessed by measurement of geometric mean titer of antibodies using the hemagglutination-inhibition (HI) assay. Vaccine response was defined as a 4-fold or higher increase of antibody titers to at least one vaccine antigen.


      Eighty-five patients received either the intradermal (n = 41) or intramuscular (n = 44) vaccine. Vaccine response was seen in 6 of 41 patients (14.6%) in the intradermal vs 8 of 43 (18.6%) in the intramuscular group (p = 0.77). Seroprotection (HI ≥1:32) was 39% for H1N1, 83% for H3N2 and 29% for B strain in the intradermal group vs 28% for H1N1, 98% for H3N2 and 58% for B strain in the intramuscular group (p = 0.36 for H1N1, p = 0.02 for H3N2, p < 0.01 for B). Mild adverse events were seen in 44% of patients in the intradermal group and 34% in the intramuscular group (p = 0.38).


      Immunogenicity of the 2008–9 influenza vaccine given intradermally or intramuscularly was overall poor in lung transplant recipients. Novel strategies for influenza vaccination in this population are needed.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to The Journal of Heart and Lung Transplantation
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Vilchez R.A.
        • McCurry K.
        • Dauber J.
        • et al.
        Influenza virus infection in adult solid organ transplant recipients.
        Am J Transplant. 2002; 2: 287-291
        • Kumar D.
        • Erdman D.
        • Keshavjee S.
        • et al.
        Clinical impact of community-acquired respiratory viruses on bronchiolitis obliterans after lung transplant.
        Am J Transplant. 2005; 5: 2031-2036
        • Danzinger-Isakov L.
        • Kumar D.
        AST Infectious Diseases Community of Practice.
        Am J Transplant. 2009; 9: S258-S262
        • Duchini A.
        • Goss J.A.
        • Karpen S.
        • et al.
        Vaccinations for adult solid-organ transplant recipients: current recommendations and protocols.
        Clin Microbiol Rev. 2003; 16: 357-364
        • Mazzone P.J.
        • Mossad S.B.
        • Mawhorter S.D.
        • et al.
        The humoral immune response to influenza vaccination in lung transplant patients.
        Eur Respir J. 2001; 18: 971-976
        • Hayney M.S.
        • Welter D.S.
        • Francois M.
        • et al.
        Influenza vaccine antibody responses in lung transplant recipients.
        Prog Transplant. 2004; 14: 346-351
        • Manuel O.
        • Humar A.
        • Chen M.H.
        • et al.
        Immunogenicity and safety of an intradermal boosting strategy for vaccination against influenza in lung transplant recipients.
        Am J Transplant. 2007; 7: 2567-2572
        • Dopp J.M.
        • Wiegert N.A.
        • Moran J.J.
        • et al.
        Effect of annual influenza immunization on antibody response in lung transplant patients.
        Prog Transplant. 2009; 19: 153-159
        • Moll H.
        Antigen delivery by dendritic cells.
        Int J Med Microbiol. 2004; 294: 337-344
        • Steinman R.M.
        • Pope M.
        Exploiting dendritic cells to improve vaccine efficacy.
        J Clin Invest. 2002; 109: 1519-1526
        • Gelinck L.B.
        • van den Bemt B.J.
        • Marijt W.A.
        • et al.
        Intradermal influenza vaccination in immunocompromised patients is immunogenic and feasible.
        Vaccine. 2009; 27: 2469-2474
        • Belshe R.B.
        • Newman F.K.
        • Cannon J.
        • et al.
        Serum antibody responses after intradermal vaccination against influenza.
        N Engl J Med. 2004; 351: 2286-2294
        • Ellis J.S.
        • Zambon M.C.
        Molecular investigation of an outbreak of influenza in the United Kingdom.
        Eur J Epidemiol. 1997; 13: 369-372
      1. Committee for Proprietary Medicinal Products (CPMP), 1997. Note for guidance on harmonisation of requirements for influenza vaccines (CPMP/BWP/214/96), 12 March 1997, pp 15-9.

        • Stewart S.
        • Fishbein M.C.
        • Snell G.I.
        • et al.
        Revision of the 1996 working formulation for the standardization of nomenclature in the diagnosis of lung rejection.
        J Heart Lung Transplant. 2007; 26: 1229-1242
        • Kenney R.T.
        • Frech S.A.
        • Muenz L.R.
        • et al.
        Dose sparing with intradermal injection of influenza vaccine.
        N Engl J Med. 2004; 351: 2295-2301
        • Halloran P.F.
        Immunosuppressive drugs for kidney transplantation.
        N Engl J Med. 2004; 351: 2715-2729
        • Scharpé J.
        • Evenepoel P.
        • Maes B.
        • et al.
        Influenza vaccination is efficacious and safe in renal transplant recipients.
        Am J Transplant. 2008; 8: 332-337
        • Salles M.J.
        • Sens Y.A.
        • Boas L.S.
        • et al.
        Influenza virus vaccination in kidney transplant recipients: serum antibody response to different immunosuppressive drugs.
        Clin Transplant. 2010; 24: E17-E23
        • Gotoh K.
        • Ito Y.
        • Suzuki E.
        • et al.
        Effectiveness and safety of inactivated influenza vaccination in pediatric liver transplant recipients over three influenza seasons.
        Pediatr Transplant. 2011; 15: 112-116
        • Leroux-Roels I.
        • Vets E.
        • Freese R.
        • et al.
        Seasonal influenza vaccine delivered by intradermal microinjection: a randomised controlled safety and immunogenicity trial in adults.
        Vaccine. 2008; 26: 6614-6619
        • Holland D.
        • Booy R.
        • De Looze F.
        • et al.
        Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial.
        J Infect Dis. 2008; 198: 650-658
        • van Damme P.
        • Arnou R.
        • Kafeja F.
        • et al.
        Evaluation of non-inferiority of intradermal versus adjuvanted seasonal influenza vaccine using two serological techniques: a randomised comparative study.
        BMC Infect Dis. 2010; 10: 134
        • Morelon E.
        • Noble C.P.
        • Daoud S.
        • et al.
        Immunogenicity and safety of intradermal influenza vaccination in renal transplant patients who were non-responders to conventional influenza vaccination.
        Vaccine. 2010; 28: 6885-6890